Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound (tirzepatide) has shown benefit in interim data from a Phase I/IIa trial.

Jeremy has more than 2200 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

TNBC is widely recognized as the most difficult breast cancer to treat because it is very aggressive and does not respond to ...

Curious where to watch all the 2026 Golden Globe-winning films and TV shows? This article guides what each film and series ...